AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25768241 — intervention group
Group type: COMPARATOR
Intervention: Hypochlorite cleaning alone
Number of subjects: 0
Study 23660437 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of the DRD2 agonist bromocriptine
Number of subjects: 0
Study 23660437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21221531 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 2 mg daily (extended 4-week pretreatment)
Number of subjects: 30
Study 21221531 — intervention group
Group type: COMPARATOR
Intervention: Usual 1-week pretreatment (placebo lead in followed by active medication)
Number of subjects: 30
Study 21221531 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (extended pretreatment)
Number of subjects: 30
Study 19604499 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable shocks
Number of subjects: 0
Study 19604499 — intervention group
Group type: COMPARATOR
Intervention: Unpredictable shocks
Number of subjects: 0
Study 16978648 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 27
Study 16978648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 15149423 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow QRS complex (QRS <120 ms)
Number of subjects: 90
Study 15149423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate QRS duration (QRS 120-150 ms)
Number of subjects: 90
Study 15149423 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide QRS complex (QRS >150 ms)
Number of subjects: 90
Study 15149423 — intervention group
Group type: COMPARATOR
Intervention: QRS duration >120 ms
Number of subjects: 90
Study 11157015 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed exercise
Number of subjects: 123
Study 11157015 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 123
Study 11157015 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 123
Study 8757207 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-strength beclomethasone dipropionate (BDP-ds) aqueous nasal spray (84 micrograms/spray), once daily
Number of subjects: 438
Study 8757207 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-strength beclomethasone dipropionate (BDP-rs) aqueous nasal spray (42 micrograms/spray), twice daily
Number of subjects: 438
Study 8757207 — intervention group
Group type: EXPERIMENTAL
Intervention: High-strength beclomethasone dipropionate (BDP-hs) aqueous nasal spray (336 micrograms/spray), once daily
Number of subjects: 438
Study 8757207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study 1590575 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 45
Study 1590575 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam/alfentanil
Number of subjects: 45
Study 1590575 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 45
Study 1590575 — intervention group
Group type: COMPARATOR
Intervention: Midazolam/alfentanil and Isoflurane
Number of subjects: 45
Study 2997101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir 250 mg/m2 once daily for four weeks
Number of subjects: 27
Study 2997101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2997101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir 250 mg/m2 once daily
Number of subjects: 27
Study 31420703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine (25 mg) plus Betahistine (8 mg) combination, administered three times a day for 1 week
Number of subjects: 162
Study 31420703 — intervention group
Group type: COMPARATOR
Intervention: Betahistine (8 mg) plus placebo, administered three times a day for 1 week
Number of subjects: 162
Study 31420703 — intervention group
Group type: COMPARATOR
Intervention: Cinnarizine (25 mg) plus placebo, administered three times a day for 1 week
Number of subjects: 162
Study 28134006 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesogenic environment
Number of subjects: 270
Study 28134006 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support for health behaviours from mothers, fathers, teachers, classmates, and close friends
Number of subjects: 270
Study 27291994 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoablation followed by autologous haemopoietic stem-cell transplantation (aHSCT)
Number of subjects: 24
Study 23617556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory physiotherapy (AP)
Number of subjects: 70
Study 23617556 — intervention group
Group type: COMPARATOR
Intervention: No physiotherapy
Number of subjects: 70
Study 22287743 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐cadherin(+) patients treated with erlotinib
Number of subjects: 95
Study 22287743 — intervention group
Group type: COMPARATOR
Intervention: E‐cadherin(‐) patients treated with placebo
Number of subjects: 95
Study 22287743 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐cadherin(‐) patients treated with erlotinib
Number of subjects: 95
Study 22287743 — intervention group
Group type: EXPERIMENTAL
Intervention: Vimentin(+) patients treated with erlotinib
Number of subjects: 95
Study 22287743 — intervention group
Group type: COMPARATOR
Intervention: Vimentin(+) patients treated with placebo
Number of subjects: 95
Study 22287743 — intervention group
Group type: COMPARATOR
Intervention: Vimentin(‐) patients treated with placebo
Number of subjects: 95
Study 19466744 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational class intervention
Number of subjects: 904
Study 19466744 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group counseling intervention
Number of subjects: 904
Study 19466744 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 904
Study 17459447 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional-set to ignore old, irrelevant distractors
Number of subjects: 0
Study 17459447 — intervention group
Group type: COMPARATOR
Intervention: Attentional-set to prioritize old items
Number of subjects: 0
Study 15237711 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analog treatment (triptorelin or leuprolide acetate)
Number of subjects: 37
Study 15237711 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group B)
Number of subjects: 37
Study 15237711 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Number of subjects: 37
Study 15237711 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin
Number of subjects: 37
Study 12055702 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 144
Study 12055702 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and atorvastatin
Number of subjects: 144
Study 12055702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin
Number of subjects: 144
Study 12055702 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 144
Study 9829494 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rHuEpo (100 U/kg)
Number of subjects: 39
Study 9829494 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rHuEpo (100 U/kg)
Number of subjects: 39
Study 9829494 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 39
Study 7917157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol, 50 mg orally four times daily for 5 days
Number of subjects: 6
Study 7917157 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide, 0.05 mg subcutaneously before and on the fifth day of cortisol administration
Number of subjects: 6
Study 2194953 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical therapeutic techniques (endoscopic sphincterotomy and biliary endoprostheses)
Number of subjects: 0
Study 2194953 — intervention group
Group type: COMPARATOR
Intervention: Surgical management
Number of subjects: 0
Study 92159 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (Dermovat) 25 g and 15 g ointment
Number of subjects: 32
Study 92159 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone-17,21-dipropionate (Diproderm) 25 g ointment
Number of subjects: 32
Study 92159 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone-17,21-dipropionate (Diproderm) 10 g ointment
Number of subjects: 32
Study 92159 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment observation
Number of subjects: 32
Study 31725676 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular stretching group (NSG) - combining transcutaneous electrical nerve stimulation with static stretching of the plantar fascia
Number of subjects: 68
Study 31725676 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study 28012176 — intervention group
Group type: EXPERIMENTAL
Intervention: UE2343 (10 mg and above)
Number of subjects: 0
Study 28012176 — intervention group
Group type: EXPERIMENTAL
Intervention: UE2343 (multiple doses)
Number of subjects: 0
Study 28012176 — intervention group
Group type: EXPERIMENTAL
Intervention: UE2343
Number of subjects: 0
Study 25889354 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g protein meal
Number of subjects: 35
Study 25889354 — intervention group
Group type: EXPERIMENTAL
Intervention: 39 g protein meal
Number of subjects: 35
Study 25889354 — intervention group
Group type: COMPARATOR
Intervention: Low-protein pancake breakfast (3 g protein)
Number of subjects: 35
Study 25889354 — intervention group
Group type: COMPARATOR
Intervention: No breakfast (water)
Number of subjects: 35
Study 23413849 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 100
Study 23413849 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine
Number of subjects: 100
Study 21104822 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy plus PAND
Number of subjects: 690
Study 21104822 — intervention group
Group type: COMPARATOR
Intervention: D2 lymphadenectomy alone
Number of subjects: 690
Study 21104822 — intervention group
Group type: EXPERIMENTAL
Intervention: TH approach
Number of subjects: 690
Study 21104822 — intervention group
Group type: COMPARATOR
Intervention: LTA approach
Number of subjects: 690
Study 19962605 — intervention group
Group type: EXPERIMENTAL
Intervention: Xbow appliance
Number of subjects: 69
Study 19962605 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 69
Study 16464325 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy (five sessions)
Number of subjects: 0
Study 16464325 — intervention group
Group type: COMPARATOR
Intervention: Usual management alone
Number of subjects: 0
Study 16464325 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy
Number of subjects: 0
Study 14679367 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 100
Study 14679367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11350703 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (10 mg to 40 mg per day)
Number of subjects: 241
Study 11350703 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem‐Solving Treatment for Primary Care (PST‐PC)
Number of subjects: 241
Study 11350703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 11350703 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment conditions
Number of subjects: 241
Study 11350703 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 241
Study 11350703 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical health component (PHC)
Number of subjects: 241
Study 11350703 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor depression (all treatments)
Number of subjects: 241
Study 9137249 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 20 ppm
Number of subjects: 8
Study 8189560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraurethral lidocaine gel (5 or 10-minute dwell time)
Number of subjects: 0
Study 8189560 — intervention group
Group type: COMPARATOR
Intervention: Plain lubricant (water-based)
Number of subjects: 0
Study 8189560 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-procedure anxiety
Number of subjects: 0
Study 8189560 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior experience with cystoscopy
Number of subjects: 0
Study 8189560 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician perception of pain
Number of subjects: 0
Study 3370061 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide 2.5 mg
Number of subjects: 12
Study 3370061 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide 5 mg
Number of subjects: 12
Study 3370061 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide 10 mg
Number of subjects: 12
Study 3370061 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide 20 mg
Number of subjects: 12
Study 3370061 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (all doses)
Number of subjects: 12
Study 3370061 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study 30931818 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of sanitary pads at home
Number of subjects: 1359
Study 30931818 — intervention group
Group type: EXPERIMENTAL
Intervention: Features of sanitation facilities (cleanliness, presence of a bin) at home
Number of subjects: 1359
Study 30931818 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive policies at school (permission to use toilet when needed)
Number of subjects: 1359
Study 30931818 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking to a friend about menstruation at school
Number of subjects: 1359
Study 30931818 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussing menstruation with parents at home
Number of subjects: 1359
Study 30059390 — intervention group
Group type: EXPERIMENTAL
Intervention: AB/HA-LLLT group (treated with low-level laser therapy)
Number of subjects: 12
Study 30059390 — intervention group
Group type: COMPARATOR
Intervention: AB/HA group (not treated with low-level laser therapy)
Number of subjects: 12
Study 30059390 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AB/HA and AB/HA-LLLT)
Number of subjects: 12
Study 30059390 — intervention group
Group type: EXPERIMENTAL
Intervention: AB/HA-LLLT group
Number of subjects: 12
Study 27993800 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line oxaliplatin/fluorouracil (OxFU)
Number of subjects: 2530
Study 27993800 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-progression survival (P-PS)
Number of subjects: 2530
Study 27993800 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line treatment
Number of subjects: 2530
Study 27993800 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line PFS and P-PS
Number of subjects: 2530
Study 25115901 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir 100 mg plus PR
Number of subjects: 90
Study 25115901 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir 300 mg plus PR
Number of subjects: 90
Study 25115901 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir 600 mg plus PR
Number of subjects: 90
Study 25115901 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus PR
Number of subjects: 90
Study 23477998 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day
Number of subjects: 785
Study 23477998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 785
Study 18675477 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF) administration
Number of subjects: 23
Study 18675477 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF associated to BMSC intracoronary infusion
Number of subjects: 23
Study 18675477 — intervention group
Group type: COMPARATOR
Intervention: HF control group
Number of subjects: 23
Study 19004228 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 87
Study 19004228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlide
Number of subjects: 87
Study 19004228 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 87
Study 19004228 — intervention group
Group type: COMPARATOR
Intervention: Control (no AD)
Number of subjects: 87
Study 19004228 — intervention group
Group type: EXPERIMENTAL
Intervention: AD (combined therapy)
Number of subjects: 87
Study 15837232 — intervention group
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Number of subjects: 459
Study 15837232 — intervention group
Group type: COMPARATOR
Intervention: Hexavac
Number of subjects: 459
Study 15837232 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 459
Study 14635412 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 10421834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) treatment in allergic asthmatic patients
Number of subjects: 0
Study 10421834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) treatment in COPD patients
Number of subjects: 0
Study 10421834 — intervention group
Group type: COMPARATOR
Intervention: Placebo group in COPD patients
Number of subjects: 0
Study 8532785 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements
Number of subjects: 0
Study 1678031 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregating platelets in internal mammary artery rings (contracted with noradrenaline)
Number of subjects: 0
Study 1678031 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregating platelets in saphenous vein rings (contracted with noradrenaline)
Number of subjects: 0
Study 1678031 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincubation of platelets with aspirin (10 mumol/l)
Number of subjects: 0
Study 1678031 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboxane receptor antagonist SQ-30741 and serotoninergic (5HT2) receptor antagonist ketanserin
Number of subjects: 0
Study 6581036 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mM diflunisal
Number of subjects: 25
Study 6581036 — intervention group
Group type: COMPARATOR
Intervention: 20 mM aspirin
Number of subjects: 25
Study 6581036 — intervention group
Group type: COMPARATOR
Intervention: 2 mM indomethacin
Number of subjects: 25
Study 6581036 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mM diflunisal
Number of subjects: 25
Study 30857261 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification and social incentives intervention
Number of subjects: 52
Study 30857261 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 28139309 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope (MAC)
Number of subjects: 30
Study 28139309 — intervention group
Group type: COMPARATOR
Intervention: Intubrite videolaryngoscope (INT)
Number of subjects: 30
Study 27183837 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care (ANC) services in the 1st trimester
Number of subjects: 19269
Study 27183837 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age <20 years, starting ANC in the 3rd trimester, short maternal stature, being firstborn, male sex
Number of subjects: 19269
Study 27183837 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age <25 years, short maternal stature, firstborns, decreased wealth
Number of subjects: 19269
Study 27183837 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age >30 years, being firstborn, short maternal stature
Number of subjects: 19269
Study 24360008 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum chloride impregnated cord
Number of subjects: 63
Study 24360008 — intervention group
Group type: EXPERIMENTAL
Intervention: Displacement paste with cap
Number of subjects: 63
Study 24360008 — intervention group
Group type: EXPERIMENTAL
Intervention: Retraction cap with paste
Number of subjects: 63
Study 24360008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimpregnated displacement cord
Number of subjects: 63
Study 24360008 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum chloride impregnated cord, displacement paste, and cap
Number of subjects: 63
Study 23040786 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 347
Study 23040786 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Number of subjects: 347
Study 23040786 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol (150 μg and 300 μg)
Number of subjects: 347
Study 23040786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 20026170 — intervention group
Group type: EXPERIMENTAL
Intervention: brief image‐based multiple behavior intervention
Number of subjects: 303
Study 20026170 — intervention group
Group type: COMPARATOR
Intervention: usual care control
Number of subjects: 303
Study 16935032 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-aerobic training (progressive resistance training)
Number of subjects: 135
Study 16935032 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (cardio respiratory fitness)
Number of subjects: 135
Study 16935032 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (minimal impact on strength or cardio respiratory fitness)
Number of subjects: 135
Study 16935032 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 135
Study 16614477 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine-related dizziness (MRD) subjects
Number of subjects: 15
Study 16614477 — intervention group
Group type: COMPARATOR
Intervention: Migraine without dizziness subjects
Number of subjects: 15
Study 16614477 — intervention group
Group type: COMPARATOR
Intervention: Headache-free controls
Number of subjects: 15
Study 12411461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cube-function technique
Number of subjects: 212
Study 12411461 — intervention group
Group type: EXPERIMENTAL
Intervention: Area-length technique
Number of subjects: 212
Study 12411461 — intervention group
Group type: COMPARATOR
Intervention: 3D cardiovascular magnetic resonance technique
Number of subjects: 212
Study 9708631 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 480 mg daily (HMA)
Number of subjects: 150
Study 9708631 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate 160 mg daily (LMA)
Number of subjects: 150
Study 9708631 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 150
Study 9708631 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (HMA, LMA, P)
Number of subjects: 150